<DOC>
	<DOCNO>NCT02432885</DOCNO>
	<brief_summary>This trial intend evaluate myocardial Fibrosis progression Duchenne Becker Muscular Dystrophy , well influence ACE inhibitor fibrosis progression . Additionally , study aim determine genetic predictor cardiac involvement dystrophy .</brief_summary>
	<brief_title>Myocardial Fibrosis Progression Duchenne Becker Muscular Dystrophy - ACE Inhibitor Therapy Trial</brief_title>
	<detailed_description>Duchenne Becker muscular dystrophy ( DMD/BMD ) diseases characterized progressive skeletal muscle degeneration replacement fibrofatty tissue . Data cardiac involvement ( define myocardial fibrosis ) , effect ACE-inhibitors specific genetic mutation myocardial involvement detect cardiac magnetic resonance ( CMR ) lacking . The study include 76 patient DMD/BMD . All patient refer two CMRs assessment ventricular function myocardial fibrosis . Patients myocardial fibrosis normal leave ventricle ejection fraction ( LVEF ) randomize two group , group receive ACE-inhibitor treatment treatment cardiomyopathy . A genetic profile perform every patient identify possible mutation related cardiac involvement .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<criteria>Patients biopsyproven Muscular Dystrophy Duchenne Becker Contraindications cardiovascular magnetic resonance imaging</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>cardiac magnetic resonance</keyword>
	<keyword>myocardial fibrosis</keyword>
	<keyword>muscular dystrophy</keyword>
</DOC>